Related Experiment Videos
Short-term chlorambucil for refractory uveitis in Behcet's disease
B A Mudun1, A Ergen, S U Ipcioglu
1Department of Ophthalmology, SSK Okmeydani Training Hospital, Mehmet Aki Bey Sokak No: 3/12, 80700 Besiktas, Istanbul, Turkey. muduna@istanbul.edu.tr
Ocular Immunology and Inflammation
|April 6, 2002
Summary
Short-term chlorambucil therapy effectively managed refractory uveitis in Behcet's disease, significantly reducing attack frequency and severity. This treatment controlled the condition in two-thirds of patients, offering a promising option for Behcet's disease management.
Area of Science:
- Ophthalmology
- Rheumatology
- Immunology
Background:
- Behcet's disease is a multisystem inflammatory disorder.
- Uveitis is a common and potentially blinding ocular manifestation of Behcet's disease.
- Refractory uveitis in Behcet's disease poses significant management challenges.
Purpose of the Study:
- To evaluate the efficacy of short-term chlorambucil therapy.
- To assess the impact on uveitis frequency and severity in Behcet's disease patients.
- To determine the long-term outcomes of this therapeutic approach.
Main Methods:
- A cohort of 44 patients with refractory uveitis due to Behcet's disease received short-term chlorambucil therapy (approx. 23 weeks).
- Attack frequency (attacks/year) and longest interval between attacks were analyzed.
- Therapy effectiveness was defined as <=1 attack/year and/or >=1 year between attacks.
Main Results:
- Mean follow-up was 51.4 months.
- Chlorambucil therapy significantly reduced mean attack frequency (4.9 to 0.9 attacks/year) and prolonged the interval between attacks (4.4 to 25.7 months).
- The proportion of severe attacks decreased, and while visual acuity varied, serious side effects were not observed.
Conclusions:
- Short-term chlorambucil therapy is effective in controlling refractory uveitis in Behcet's disease for approximately two-thirds of patients.
- The treatment demonstrates a significant reduction in disease activity and severity.
- Further research may explore optimal duration and combination therapies.